Who are VTAMA®'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Trifarotene Vehicle, Trifarotene cream, Bexarotene (Targretin LGD1069), CD5789 (trifarotene), AGN-229666.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/vtama.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

VTAMA® — Competitive Intelligence Brief

VTAMA® (VTAMA®) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Retinoid X receptor (RXR) agonist. Area: Dermatology.

marketed Retinoid X receptor (RXR) agonist Retinoid X receptor (RXR) Dermatology Small molecule Live · refreshed every 30 min

Target snapshot

VTAMA® (VTAMA®) — Teva Pharmaceuticals USA. VTAMA is a topical retinoid that binds to and activates retinoid X receptors (RXR) to promote skin cell differentiation and reduce inflammation in psoriasis.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
VTAMA® TARGET	VTAMA®	Teva Pharmaceuticals USA	marketed	Retinoid X receptor (RXR) agonist	Retinoid X receptor (RXR)
Trifarotene Vehicle	Trifarotene Vehicle	Galderma R&D	marketed	Retinoid X receptor (RXR) agonist	Retinoid X receptor (RXR)
Trifarotene cream	Trifarotene cream	Galderma R&D	marketed	Selective retinoid X receptor (RXR) agonist	Retinoid X receptor (RXR)
Bexarotene (Targretin LGD1069)	Bexarotene (Targretin LGD1069)	Beersheva Mental Health Center	phase 3	Retinoid X receptor (RXR) agonist	RXR (Retinoid X Receptor)
CD5789 (trifarotene)	CD5789 (trifarotene)	Galderma R&D	phase 3	Selective retinoid X receptor (RXR) agonist	Retinoid X receptor (RXR)
AGN-229666	AGN-229666	Allergan	phase 3	Retinoid X receptor (RXR) agonist	RXR (Retinoid X Receptor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Retinoid X receptor (RXR) agonist class)

Allergan · 1 drug in this class
Beersheva Mental Health Center · 1 drug in this class
Galderma R&D · 1 drug in this class
Teva Pharmaceuticals USA · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). VTAMA® — Competitive Intelligence Brief. https://druglandscape.com/ci/vtama. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab